So here's a story about a company doing something smart and strategic, and its stock doing... something else entirely. Tempus AI Inc. (TEM) said Thursday it expanded its multi-year collaboration with Gilead Sciences Inc. (GILD) to support oncology research using real-world evidence. The stock, perhaps predictably, rose about 3.7% in premarket trading Friday to $45.79. But if you look under the hood, the market's reaction to this good news is happening against a pretty rough technical backdrop.

Gilead, the big biopharma company, isn't new to Tempus's data. They've already been using Tempus's de-identified, multimodal data for stuff like trial design, picking which diseases to target, figuring out biomarker strategies, and analyzing health outcomes. The expanded deal is basically Gilead getting the all-access pass: enterprise-wide access to Tempus's AI-driven Lens platform, broader datasets across more types of cancer, and Tempus's analytical services on tap. It's the kind of deal that makes sense—a data-rich AI shop partnering with a deep-pocketed drug developer to try to find better cancer treatments faster.

Good News on the Clinical Front, Too

Separately, but probably adding to the positive vibe, Tempus recently reported some encouraging results from something called the ALERT trial. This isn't about the cancer data deal; it's about an automated system that pings doctors through electronic health records. The study showed this system led to a 40% relative increase in life-saving valve procedures and a 27% rise in evaluations by multidisciplinary heart teams within 90 days. So, Tempus isn't just a data warehouse; it's building tools that seem to actually change clinical practice, which is the whole point.

Now, About That Stock Chart...

Here's where the story gets a bit more complicated. All this good news is landing while Tempus's stock chart looks... unwell. As of the last close at $44.30, the stock is trading 6.4% below its 20-day simple moving average and 14.9% below its 50-day average. That's generally read as a bearish short-term trend. It's also a whopping 26.7% below its 100-day average, suggesting selling pressure has been persistent.

The technical indicators are giving mixed signals, like they often do. The Relative Strength Index (RSI) is at 36.60, which is in neutral territory—not oversold, not overbought. But the Moving Average Convergence Divergence (MACD) is showing a bullish crossover. For the non-chartists: the MACD line is at -1.9806 and has crossed above its signal line at -2.2676. This hints that while the stock is under pressure, the momentum might be trying to turn positive.

Traders are watching two key levels. Resistance—where sellers might show up—is seen around $51.00. Support—where buyers might step in—is down near $41.50. The premarket pop is moving it away from that support level, for now.

What the Analysts and the Numbers Say

The analyst community is still firmly in the bull camp. The consensus rating is a Buy, with an average price target of $72.00. That's a lot of upside from current levels. Recent moves include Guggenheim lowering its target to $60 (but keeping a Buy rating) on March 30, Needham maintaining a $75 target on March 11, and HC Wainwright & Co. raising its target all the way to $95 on March 9.

The company is scheduled to report its next earnings around May 5, 2026. The estimates tell a classic growth-story-in-progress tale: analysts expect a loss of 29 cents per share, which is wider than the loss of 24 cents previously. But they also expect revenue to jump to $345.43 million, up significantly from $255.74 million. Losing more money to make much more money—the Silicon Valley special.

Despite the analyst love, a broader market signal suggests Tempus is struggling for traction. Its momentum score is weak, indicating the stock is underperforming the broader market. Good partnerships and growth potential are one thing; getting the market to consistently reward them is another.

The ETF Angle: A Double-Edged Sword

Here's a crucial piece of context for how Tempus trades. It's not just a standalone stock; it's a meaningful holding in some popular, and famously volatile, exchange-traded funds. Specifically, it's a 5.32% weight in the ARK Innovation ETF (ARKK) and an 8.79% weight in the ARK Genomic Revolution ETF (ARKG).

This matters because of how ETFs work. If investors pour money into ARKK or ARKG, the fund managers have to go out and buy more Tempus stock to keep the fund's composition right. Conversely, big outflows force selling. So, Tempus's price action can sometimes be driven less by its own news and more by whether Cathie Wood's ARK funds are having a good or bad week. It adds a layer of mechanical, non-fundamental trading pressure that investors need to be aware of.

So, to sum up: Tempus AI is doing the right things—expanding a marquee partnership, reporting positive clinical trial results, and growing revenue. The stock got a nice premarket bump on the Gilead news. But it's doing all this while climbing out of a technical hole, fighting weak market momentum, and being a passenger in the sometimes-rocky ARK ETF boat. It's a reminder that in the markets, a good story and a good stock price don't always arrive at the same time.